Table 2 Baseline characteristics
Baseline characteristics | Asymptomatic with treatment | Asymptomatic without treatment | p-value |
|---|---|---|---|
n (%) | n (%) | ||
Total | 19 (45) | 23 (55) | |
Demographics and CF characteristics | |||
Age, years (median (IQR)) | 19.2 (11.4–33.5) | 20.2 (12.7–29.1) | 0.86 |
Female sex | 7 (37) | 9 (39) | 0.88 |
Homozygous DeltaF508 | 8 (42) | 14 (61) | 0.23 |
CF-related diabetes | 7 (37) | 6 (26) | 0.45 |
Pancreatic insufficiency | 19 (100) | 21 (91) | 0.49 |
CF centre | 0.00 | ||
Gothenburg (n = 14) | 0 | 14 | |
Lund (n = 11) | 9 | 2 | |
Stockholm (n = 15) | 10 | 5 | |
Uppsala (n = 2) | 0 | 2 | |
Microorganisms | |||
Chronic PsA colonization | 8 (42) | 3 (15) | 0.06 |
Treatments | |||
Inhaled antibiotics | 9 (50) | 12 (54) | 0.78 |
Inhaled corticosteroids | 2 (11) | 8 (35) | 0.08 |
Macrolides | 5 (26) | 3 (13) | 0.43 |
Inhaled rhDNase | 7 (37) | 5 (22) | 0.28 |
Lung function and other clinical parameters | |||
ppFEV1 (mean ± SD) | 76.1 ± 22.6 | 82.0 ± 24.3 | 0.45 |
ppFVC (median (IQR)) | 100.0 (79.2–104.7) | 94.7 (86.5–107.2) | 0.67 |
Number of IV-antibiotics (median (IQR)) | 1 (0–3) | 1 (0–3.25) | 0.84 |
Hospitalization days (median (IQR)) | 0 (0–3.5) | 0 (0–2.25) | 0.88 |
Total IgE (median (IQR))a | 18.0 (9.1–88.5) | 41.0 (10.7–55.3) | 0.73 |
Eosinophils (median (IQR))b | 0.2 (0.1–0.4) | 0.2 (0.1–0.3) | 0.58 |